BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Lupus Nephritis readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Lupus Nephritis\, fro
 m ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07229742-11089@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:SHR-2173: Phase 2 readout est. (NCT07229742)
DESCRIPTION:SHR-2173\, phase 2\, Lupus Nephritis.\nStudy: A Phase II Clinic
 al Study on the Efficacy and Safety of SHR-2173 Injection in the Treatment
  of Patients With Active Lupus Nephritis\nEstimated primary completion: Ju
 ne 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/shr-2173#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0722974
 2
URL:https://assetmemo.bio/drug/shr-2173#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06406205-1793@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Lupkynis (Voclosporin): Phase 3 readout est. (NCT06406205)
DESCRIPTION:Lupkynis (Voclosporin)\, phase 3\, Systemic Lupus Erythematosus
 .\nStudy: A Study of QLG1074 Combined With Background Therapy in Subjects 
 With Active Lupus Nephritis\nEstimated primary completion: June 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/voclosporin#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06406205
URL:https://assetmemo.bio/drug/voclosporin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06419205-5759@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Ebribafusp alfa: Phase 2 readout est. (NCT06419205)
DESCRIPTION:Ebribafusp alfa\, phase 2\, IgA Nephropathy.\nStudy: A Phase 2 
 Study to Evaluate the Safety\, PD\, PK\, and Clinical Activity of ADX-097 
 in Participants With IgAN\, LN or C3G\nEstimated primary completion: Febru
 ary 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ebribafusp-
 alfa#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06419205
URL:https://assetmemo.bio/drug/ebribafusp-alfa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06581198-11270@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20280214
DTEND;VALUE=DATE:20280215
SUMMARY:Rapcabtagene autoleucel: Phase 2 readout est. (NCT06581198)
DESCRIPTION:Rapcabtagene autoleucel\, phase 2\, Lupus Nephritis.\nStudy: A 
 Study of Rapcabtagene Autoleucel in Active\, Refractory Systemic Lupus Ery
 thematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)\nEs
 timated primary completion: 14 February 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/rapcabtagene-autoleucel#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT06581198
URL:https://assetmemo.bio/drug/rapcabtagene-autoleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05039619-2649@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20280615
DTEND;VALUE=DATE:20280616
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT05039619)
DESCRIPTION:Obinutuzumab\, phase 2\, Lupus Nephritis.\nStudy: A Study to Ev
 aluate the Efficacy\, Safety\, and Pharmacokinetics of Obinutuzumab in Ado
 lescents With Active Class III or IV Lupus Nephritis and the Safety and PK
  of Obinutuzumab in Pediatric Participants\nEstimated primary completion: 
 15 June 2028. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/obinutu
 zumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT05039619
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07767188-2649@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20290227
DTEND;VALUE=DATE:20290228
SUMMARY:Obinutuzumab: Phase 3 readout est. (NCT07767188)
DESCRIPTION:Obinutuzumab\, phase 3\, Lupus Nephritis.\nStudy: A Trial to Ex
 plore the Efficacy and Safety of O-triple as Initial Therapy in the Active
  Lupus Nephritis Patients (INITIAL Trial)\nEstimated primary completion: 2
 7 February 2029. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/obin
 utuzumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07767188
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07721363-2649@assetmemo.bio
DTSTAMP:20261121T005623Z
DTSTART;VALUE=DATE:20290902
DTEND;VALUE=DATE:20290903
SUMMARY:Obinutuzumab: Phase 2 readout est. (NCT07721363)
DESCRIPTION:Obinutuzumab\, phase 2\, Lupus Nephritis.\nStudy: Obinutuzumab 
 for Systemic Lupus Erythematosus Pure Membranous Nephropathy: a Phase II T
 rial\nEstimated primary completion: 2 September 2029. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/obinutuzumab#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07721363
URL:https://assetmemo.bio/drug/obinutuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
